Relmada Therapeutics is a clinical-stage biotechnology company focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity that addresses areas of medical need in the treatment of central nervous system diseases and other disorders. Co.'s primary product candidate, esmethadone, is being developed as an acting, oral agent for the treatment of depression and other potential indications. The RLMD average annual return since 2015 is shown above.
The Average Annual Return on the RLMD average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RLMD average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RLMD average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free RLMD Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
